Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial

Affiliations

• ¹ Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. k.weisel@uke.de.
• ² Department of Hematology, Oncology, Immunology, Rheumatology and Pulmonology, University Hospital of Tuebingen, Tuebingen, Germany. k.weisel@uke.de.
• ³ Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany.
• ⁴ Center for Clinical Trials, University Hospital of Tuebingen, Tuebingen, Germany.
• ⁵ Department of Hematology, Oncology, Immunology, Rheumatology and Pulmonology, University Hospital of Tuebingen, Tuebingen, Germany.
• ⁶ Department of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
• ⁷ Clinic of Internal Medicine III, Hematology and Oncology, Clinic of Chemnitz, Chemnitz, Germany.
• ⁸ Department of Hematology, University Hospital Essen, Essen, Germany.
• ⁹ Department of Hematology, Oncology, and Pneumology, University Medical Center Mainz, Mainz, Germany.
• ¹⁰ Clinic for Haematology/Oncology, Catholic Hospital Hagen, Hagen, Germany.
• ¹¹ Division of Biostatistics, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany.
• ¹² Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany.
• ¹³ Department of Hematology and Oncology, Asklepios Hospital Hamburg Altona, Hamburg, Germany.
• ¹⁴ National Center for Tumor Diseases (NCT), University Clinic Heidelberg, Heidelberg, Germany.